{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:04:48Z","timestamp":1778796288112,"version":"3.51.4"},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T00:00:00Z","timestamp":1531180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["1 I01 CX000920-01"],"award-info":[{"award-number":["1 I01 CX000920-01"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["2I01CX000920-04"],"award-info":[{"award-number":["2I01CX000920-04"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0200442","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T18:04:43Z","timestamp":1531245883000},"page":"e0200442","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Activity of ceftolozane-tazobactam against Escherichia coli isolates from U.S. veterans (2011) in relation to co-resistance and sequence type 131 (ST131) H30 and H30Rx status"],"prefix":"10.1371","volume":"13","author":[{"given":"Brian D.","family":"Johnston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Thuras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9588-5045","authenticated-orcid":true,"given":"James R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,7,10]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/cid\/cit503","article-title":"<italic>Escherichia coli<\/italic> sequence type 131 (ST131) as an emergent multidrug-resistant pathogen among U.S. veterans","volume":"57","author":"A Colpan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1086\/653932","article-title":"<italic>Escherichia coli<\/italic> sequence type ST131 as the major cause of serious multidrug-resistant <italic>E<\/italic>. <italic>coli<\/italic> infections in the United States (2007)","volume":"51","author":"JR Johnson","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"ofx089","DOI":"10.1093\/ofid\/ofx089","article-title":"The pandemic <italic>H<\/italic>30 subclone of sequence type 131 (ST131) is the leading cause of multidrug-resistant <italic>Escherichia coli<\/italic> infections in the United States (2011\u20132012)","volume":"4","author":"JR Johnson","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"ref4","first-page":"e00377","article-title":"The epidemic of ESBL-producing <italic>Escherichia coli<\/italic> ST131 is driven by a single highly virulent subclone, H30-Rx","volume":"6","author":"LB Price","year":"2013","journal-title":"mBio"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e02162","DOI":"10.1128\/mBio.02162-15","article-title":"Evolutionary history of the global emergence of the <italic>Escherichia coli<\/italic> epidemic clone ST131","volume":"7","author":"N Stoesser","year":"2016","journal-title":"mBio"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/jac\/dkv017","article-title":"CTX-M-27- and CTX-M-14-producing, ciprofloxacin-resistant <italic>Escherichia coli<\/italic> of the <italic>H<\/italic>30 subclonal group within ST131 drive a Japanese regional ESBL epidemic","volume":"70","author":"Y Matsumura","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1128\/AAC.05824-11","article-title":"Molecular epidemiology of <italic>Escherichia coli<\/italic> sequence type ST131 (O25:H4) and <italic>bla<\/italic>CTX-M-15 among extended-spectrum cephalosporinase-producing <italic>E<\/italic>. <italic>coli<\/italic> in the United States (2000\u20132009)","volume":"56","author":"JR Johnson","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1128\/AAC.01604-13","article-title":"Molecular epidemiology of <italic>Escherichia coli<\/italic> sequence type ST131 and its H30 and H30-Rx subclones among extended-spectrum beta-lactamase-positive and -negative <italic>E<\/italic>. <italic>coli<\/italic> clinical isolates from the Chicago region (2007\u20132010)","volume":"57","author":"R Banerjee","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1128\/JCM.00346-13","article-title":"Prevalence and characteristics of the epidemic multi-resistant <italic>Escherichia coli<\/italic> ST131 clonal group among extended-spectrum \u03b2-lactamase (ESBL)-producing <italic>E<\/italic>. <italic>coli<\/italic> in Copenhagen","volume":"51","author":"B Olesen","year":"2013","journal-title":"J Clin Microbiol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1128\/AAC.00673-15","article-title":"Intensity and mechanisms of fluoroquinolone resistance within the H30 and H30Rx subclones of <italic>Escherichia coli<\/italic> sequence type 131 vs. other fluoroquinolone-resistant <italic>E<\/italic>. <italic>coli<\/italic>","volume":"59","author":"JR Johnson","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"ref11","unstructured":"Sucher AJ, Chahine EB, Cogan P, Fete M. Ceftolozane\/tazobactam: a new cephalosporin and nd of fluoroquinolone resistance within the H30 and H30Rx subclones"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40265-015-0524-5","article-title":"Ceftolozane\/tazobactam: a review in complicated intra-abdominal and urinary tract infections","volume":"76","author":"LJ Scott","year":"2016","journal-title":"Drugs"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/jac\/dkw374","article-title":"Efficacy of ceftolozane\/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing <italic>Escherichia coli<\/italic> and <italic>Klebsiella pneumoniae<\/italic>: a pooled analysis of Phase 3 clinical trials","volume":"72","author":"MW Popejoy","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/jac\/dkx136","article-title":"Activity of ceftolozane\/tazobactam against surveillance and \u2018problem\u2019 Enterobacteriaceae, <italic>Pseudomonas aeruginosa<\/italic> and non-fermenters from the British Isles","volume":"72","author":"DM Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/jac\/dkx009","article-title":"Ceftolozane\/tazobactam activity against drug-resistant Enterobacteriaceae and <italic>Pseudomonas aeruginosa<\/italic> causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012\u201315)","volume":"72","author":"MA Pfaller","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1128\/CMR.00125-13","article-title":"<italic>Escherichia coli<\/italic> ST131, an intriguing clonal group","volume":"27","author":"M Nicolas-Chanoine","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1128\/AAC.00297-09","article-title":"Epidemic clonal groups of <italic>Escherichia coli<\/italic> as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002\u20132004","volume":"53","author":"JR Johnson","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref18","year":"2012"},{"key":"ref19","year":"2017"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"K Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1128\/AAC.01025-12","article-title":"Clonal composition and community clustering of drug-susceptible and -resistant <italic>Escherichia coli<\/italic> isolates from bloodstream infections","volume":"57","author":"S Adams-Sapper","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1101\/gr.180190.114","article-title":"Large-scale genomic sequencing of extraintestinal pathogenic <italic>Escherichia coli<\/italic> strains","volume":"15","author":"SJ Salipante","year":"2015","journal-title":"Genome Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.diagmicrobio.2015.10.016","article-title":"Prevalence and characteristics of <italic>Escherichia coli<\/italic> sequence type 131 and its <italic>H<\/italic>30 and <italic>H<\/italic>30Rx subclones: a multicenter study from Korea","volume":"84","author":"SY Kim","year":"2016","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0200442","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T05:22:07Z","timestamp":1661577727000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0200442"}},"subtitle":[],"editor":[{"given":"William M.","family":"Shafer","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,7,10]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0200442","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,10]]}}}